LIFE
EXPLOSION

Our Mission

Our mission is to foster a “Life Explosion” that enriches the lives of people around the world. In pursuit of this mission, we maintain the goal of delivering cures and hope to patients with unmet medical needs.

News

ALL

      Regenerative Medicine

      Development Status

      iPSC Regenerative Medicine

      【Ophthalmology Area】

      Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
      HLCR011 Wet AMD Japan
      Joint development with Sumitomo Dainippon Pharma
      Undergoing preparation for clinical trial
      Development Code Indication Market Pre-clinical test Phase I Trial Phase II Trial Phase III Trial Apply-approve On the Market Progress Status
      HLCR012 Dry AMD US
      EU

      【Liver Disease】

      Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
      HLCL041 Metabolic Liver Disease Japan
      Joint research with Yokohama City University

      【Immuno Oncology】

      Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
      HLCN061 Solid Tumors Japan
      Healios is promoting R&D
      Development Code Indication Market Pre-clinical test Phase I Trial Phase II Trial Phase III Trial Apply-approve On the Market Progress Status
      HLCN061 Solid Tumors US
      Healios is promoting R&D
      1. NK (Natural killer) cells : NK cells are a subset of lymphocytes, a type of white blood cell. NK cells play a central role in a cell mediated defense system that human bodies naturally have, and attack cancer cells and virus-infected cells.

      Somatic Stem Cell Regenerative Medicine

      Development Code Indication Market Pre-clinical test Apply-approve On the Market Progress Status
      HLCM051 Ischemic Stroke Japan
      Clinical trial (TREASURE study) ongoing
      HLCM051 ARDS Japan
      Clinical trial (ONE-BRIDGE study) ongoing

      Development Fields